640 related articles for article (PubMed ID: 30219367)
1. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.
Fortner KB; Swamy GK; Broder KR; Jimenez-Truque N; Zhu Y; Moro PL; Liang J; Walter EB; Heine RP; Moody MA; Yoder S; Edwards KM
Vaccine; 2018 Oct; 36(42):6354-6360. PubMed ID: 30219367
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
[TBL] [Abstract][Full Text] [Related]
3. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
4. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
Wanlapakorn N; Maertens K; Chaithongwongwatthana S; Srimuan D; Suratannon N; Vongpunsawad S; Tran TMP; Hens N; Van Damme P; Locht C; Poovorawan Y; Leuridan E
Vaccine; 2018 Mar; 36(11):1453-1459. PubMed ID: 29426663
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial.
Munoz FM; Bond NH; Maccato M; Pinell P; Hammill HA; Swamy GK; Walter EB; Jackson LA; Englund JA; Edwards MS; Healy CM; Petrie CR; Ferreira J; Goll JB; Baker CJ
JAMA; 2014 May; 311(17):1760-9. PubMed ID: 24794369
[TBL] [Abstract][Full Text] [Related]
7. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
[TBL] [Abstract][Full Text] [Related]
8. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
[TBL] [Abstract][Full Text] [Related]
9. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
Barug D; Pronk I; van Houten MA; Versteegh FGA; Knol MJ; van de Kassteele J; Berbers GAM; Sanders EAM; Rots NY
Lancet Infect Dis; 2019 Apr; 19(4):392-401. PubMed ID: 30938299
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India.
Sharma HJ; Parekh S; Pujari P; Shewale S; Desai S; Kawade A; Ravi M; Oswal J; James S; Mahantashetti N; Munshi R; Ghosh A; Rao V; Balsubramaniam S; Varughese P; Somshekhar A; Ginsburg AS; Rao H; Gautam M; Gairola S; Shaligram U
Expert Rev Vaccines; 2023; 22(1):278-287. PubMed ID: 36883291
[TBL] [Abstract][Full Text] [Related]
11. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response.
Halperin SA; Langley JM; Ye L; MacKinnon-Cameron D; Elsherif M; Allen VM; Smith B; Halperin BA; McNeil SA; Vanderkooi OG; Dwinnell S; Wilson RD; Tapiero B; Boucher M; Le Saux N; Gruslin A; Vaudry W; Chandra S; Dobson S; Money D
Clin Infect Dis; 2018 Sep; 67(7):1063-1071. PubMed ID: 30010773
[TBL] [Abstract][Full Text] [Related]
13. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
16. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
[TBL] [Abstract][Full Text] [Related]
17. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
[TBL] [Abstract][Full Text] [Related]
18. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.
Wanlapakorn N; Maertens K; Thongmee T; Srimuan D; Thatsanathorn T; Van Damme P; Leuridan E; Poovorawan Y
Vaccine; 2020 Oct; 38(44):6914-6921. PubMed ID: 32888740
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of pertussis, tetanus, and diphtheria antibodies in sera and breast milk from Tdap vaccinated women using a qualified multiplex assay.
Portillo S; Oshinsky J; Williams M; Yoder S; Liang Y; Campbell JD; Laufer MK; Neuzil KM; Edwards KM; Pasetti MF
mSphere; 2024 Apr; 9(4):e0052723. PubMed ID: 38497618
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases.
Van den Steen P; Cheuvart B; Deraedt Q; Valdes Verelst L; Shamarina D
Hum Vaccin Immunother; 2023 Dec; 19(1):2159731. PubMed ID: 36746754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
